Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.
Yi HuXin XuYao-Bin OuyangCong HeNian-Shuang LiChuan XieChao PengZhen-Hua ZhuYong XieXu ShuNong Hua LuYin ZhuPublished in: Helicobacter (2022)
Neither 7- or 10-day VA dual therapy with b.i.d. or t.i.d. amoxicillin provides satisfied efficacy as the first-line treatment for H. pyloriinfection in China. Further optimization is needed.
Keyphrases